SenesTech (SNES) Given New $14.00 Price Target at Roth Capital

SenesTech (NASDAQ:SNES) had its target price reduced by Roth Capital from $3.75 to $14.00 in a research report report published on Thursday. They currently have a buy rating on the stock.

Other equities research analysts also recently issued research reports about the stock. Craig Hallum set a $3.00 target price on shares of SenesTech and gave the stock a buy rating in a research report on Wednesday, November 22nd. Zacks Investment Research raised shares of SenesTech from a sell rating to a hold rating in a research report on Thursday, October 12th.

SenesTech (NASDAQ:SNES) traded up $0.06 during mid-day trading on Thursday, reaching $0.66. 324,500 shares of the company’s stock traded hands, compared to its average volume of 160,686. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.94 and a quick ratio of 2.67. SenesTech has a 12-month low of $0.56 and a 12-month high of $10.69.

SenesTech (NASDAQ:SNES) last announced its quarterly earnings results on Wednesday, November 8th. The company reported ($0.28) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.31) by $0.03. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.25 million. SenesTech had a negative net margin of 14,473.40% and a negative return on equity of 190.41%. sell-side analysts expect that SenesTech will post -1.16 EPS for the current year.

Several large investors have recently modified their holdings of the company. White Pine Capital LLC acquired a new stake in SenesTech during the second quarter valued at approximately $110,000. Prudential PLC lifted its holdings in shares of SenesTech by 49.3% during the 2nd quarter. Prudential PLC now owns 447,971 shares of the company’s stock worth $2,661,000 after acquiring an additional 147,971 shares during the period. Skylands Capital LLC lifted its holdings in shares of SenesTech by 139.8% during the 3rd quarter. Skylands Capital LLC now owns 87,483 shares of the company’s stock worth $162,000 after acquiring an additional 51,000 shares during the period. TCI Wealth Advisors Inc. bought a new position in shares of SenesTech during the 3rd quarter worth about $748,000. Finally, Gilder Gagnon Howe & Co. LLC lifted its holdings in shares of SenesTech by 3.0% during the 3rd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,078,499 shares of the company’s stock worth $1,995,000 after acquiring an additional 31,330 shares during the period. 14.44% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was first posted by Week Herald and is owned by of Week Herald. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at

About SenesTech

SenesTech, Inc is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes.

Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with's FREE daily email newsletter.

Leave a Reply